Elsevier officially released the 2024 CiteScore in Scopus, the most comprehensive multidisciplinary literature database in the world. The update of CiteScore reflects the changing trends in the global research field. It not only provides a decision-making basis for global researchers, but also offers scientific evaluation of journal impact.

This year, a total of 4 Open Exploration journals received CiteScores. Of these, Exploration of Targeted Anti-tumor Therapy and Exploration of Immunology have demonstrated exceptional performance, highlighting their significant growth potential in respective disciplines. We're also pleased to share that Exploration of Neuroprotective Therapy received a CiteScore for the first time. Below is the detailed information of the 2024 CiteScores for 4 journals.

Exploration of Medicine

The 2024 CiteScore of Exploration of Medicine (EM) was 1.8, remaining stable compared to the previous years. This indicates that the journal has a stable readership, confirming its resilience for continuous development. Meanwhile, among 668 journals in General Medicine, EM ranked 267th, located in the Q2 region. Our editorial teams will continue to collaborate closely with experienced reviewers and authors while continuously refining all aspects of the publishing process, thereby enhancing the journal's growth and academic impact.

Exploration of Targeted Anti-tumor Therapy

The 2024 CiteScore of Exploration of Targeted Anti-tumor Therapy (ETAT) reached 3.1, up from 2.8 of 2023 CiteScore and 1.7 of 2022 CiteScore. This result reflects the journal's steady growth in citations and increased visibility across the oncology fields. This significant achievement has not only strengthened the resolve of the journal's editorial teams, peer reviewers, and contributing authors but also reaffirmed the academic community's unwavering confidence in fostering impactful research through collaborative efforts.

Exploration of Immunology

The 2024 CiteScore of Exploration of Immunology (EI) reached 1.5, with an increase of 50% from 2023 CiteScore. This means that an increasing number of researchers are paying attention to EI journals and articles published in it have had a wider impact in academia.

Exploration of Neuroprotective Therapy

The 2024 CiteScore of Exploration of Neuroprotective Therapy (ENT) was 2.0, marking its first score in the Scopus database. Over the past few years, ENT has been progressively indexed in authoritative databases, which intrinsically correlates with its unwavering adherence to rigorous peer review and editorial policies. The 2024 CiteScore of ENT is an important step for the journal to gain academic recognition and also a milestone in its development.

We express our deepest appreciation to our esteemed Editors-in-Chief, dedicated Editorial Board members, rigorous reviewers, prolific authors, and loyal readers for their dedication and contributions, that have made these achievements. We will make greater efforts to promote the sustainable development of all journals and strive to achieve even greater achievements in the future.

Data Source: 2024 CiteScores™ (Elsevier)